Literature DB >> 1526628

Acromegaly with 'normal' serum growth hormone levels. Clinical features, diagnosis and results of transsphenoidal microsurgery.

S J Brockmeier1, M Buchfelder, E F Adams, W Schott, R Fahlbusch.   

Abstract

Among 216 consecutive patients with growth hormone secreting pituitary adenomas who underwent primary neurosurgical treatment at the University of Erlangen-Nürnberg, 8 cases of acromegaly with 'normal' basal growth hormone levels (less than or equal to 5 ng/ml) were seen. They all had the typical clinical features of acromegaly, exhibited an abnormal growth hormone secretion following an oral glucose load, and had markedly elevated somatomedin C levels. The GRH- and TRH/GnRH-tests were not found helpful in establishing the diagnosis. Neuroradiology could demonstrate a pituitary adenoma in all of the patients. Following transsphenoidal microsurgical resection of the tumours, growth hormone secretion during oral glucose tolerance testing was normalised in 7 of the 8 patients. Immunohistology and explant culture studies documented growth hormone secreting pituitary adenomas in all cases. The authors conclude that even the finding of repetitive 'normal' (less than or equal to 5 ng/ml) serum GH levels does not exclude active acromegaly and when the clinical diagnosis of acromegaly is suspected, dynamic endocrine testing may reveal abnormal secretion patterns of GH in these cases. Transsphenoidal microsurgical resection of a pituitary adenoma offers a good chance of clinical and endocrinological remission in these cases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1526628     DOI: 10.1055/s-2007-1003342

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  4 in total

Review 1.  Reevaluation of conventional pituitary irradiation in the therapy of acromegaly.

Authors:  C A Jaffe
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

2.  Acromegaly with normal growth hormone levels: response to Sandostatin-LAR treatment.

Authors:  I Shimon; D Nass; M Hadani
Journal:  Pituitary       Date:  2000-05       Impact factor: 4.107

3.  A non-acromegalic case of multiple endocrine neoplasia type 1 accompanied by a growth hormone-releasing hormone-producing pancreatic tumor.

Authors:  H Sugihara; T Shibasaki; A Tatsuguchi; F Okajima; S Wakita; Y Nakajima; K Tanimura; H Tamura; S Ishii; J Kamegai; H Akasu; W Kitagawa; K Shimizu; Y Nakamura; E Uchida; T Tajiri; Z Naito; H Katakami; S Oikawa
Journal:  J Endocrinol Invest       Date:  2007-05       Impact factor: 4.256

Review 4.  Acromegaly. Recognition and treatment.

Authors:  C A Jaffe; A L Barkan
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.